SEPTEMBER 2016Cover photo: PATH/Kelsey Barrett

PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve health, especially among women and children. We accelerate innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovations—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver measurable results that disrupt the cycle of poor health.

www.path.org

Resources and information

Tests

Ordering, manufacturing, and distribution of SD BIOLINE onchocerciasis and LF rapid tests are provided by Standard Diagnostics, Inc. Visit www.standardia.com for ordering information.

QA program

Quality assurance program materials for the tests are available at go.path.org/dx-qa.

Email dxinfo@path.org to request training, proficiency, quality assurance, and quality control panels.

Learn more at:

go.path.org/oncho | go.path.org/oncholf | go.path.org/LF

Ensuring HigH-Quality rEsults with Rapid tests foR onchoceRciasis and Lymphatic fiLaRiasis suRveiLLance

Rapid tests for onchocerciasis and lymphatic filariasis surveillanceEasy to use, point-of-care tests to monitor progress toward elimination

Three rapid tests for detecting exposure to onchocerciasis and lymphatic filariasis (LF) are now available from Standard Diagnostics, Inc. These tests are intended for use in surveillance and to guide decision-making around stopping mass drug administration (MDA).

Ordering informationVisit www.standardia.com to order tests.

These three test kits:

• Use finger prick blood samples (10 µL). • Are intended for use in regions with a history of MDA for onchocerciasis and/or lymphatic filariasis.• Detect antibodies to the Ov16 onchocerciasis antigen and/or Wb123 LF antigen (Wucheria bancrofti). • Contain 25 tests per kit.• Expire 24 months from manufacture.

SD BIOLINE Onchocerciasis IgG4 rapid test Detects antibodies specific to the Ov16 onchocerciasis antigen.

CATALOG NUMBER: 61FK10

SD BIOLINE Lymphatic Filariasis IgG4 rapid testDetects antibodies specific to the Wb123 LF antigen (Wucheria bancrofti).

CATALOG NUMBER: 61FK30

SD BIOLINE Onchocerciasis and Lymphatic Filariasis IgG4 biplex rapid testDetects antibodies to the Ov16 onchocerciasis antigen and the Wb123 LF antigen (Wucheria bancrofti).

CATALOG NUMBER: 61FK20

SD BIOLINE Oncho/LF IgG4 biplex rapid test.

Quality assurance programQuality assurance (QA) is essential to help disease elimination programs monitor and improve the quality of testing. PATH has developed materials to support QA for use of the SD BIOLINE onchocerciasis and LF rapid tests.

Training resources

• Training resources are available for individual test users and program managers on the SD BIOLINE onchocerciasis and LF rapid tests.

• AVAILABLE MATERIALS: Training panels; data collection forms; videos and instructions for running tests and best practices for blood collection and finger prick.

PATH

/Alli

son

Gol

den

Quality assurance program materials can be downloaded from go.path.org/dx-qa.

Email dxinfo@path.org to request training, proficiency, QA, and quality control panels.

Implementation resources

• Resources to support field use of tests, improve inter-reader reliability, and ensure that tests function properly.

• Materials for program managers and researchers to integrate QA into surveillance activities.

• AVAILABLE MATERIALS: Proficiency panels; study start and daily quality control panels; data collection forms; videos and instructions; example study flows; supply lists; QA ordering calculator.

C

Onchocerciasis lgG4

T

add sampLe

90°add

4 dRops of assay diLuent